Ann: ASX Relisting and Market Update, page-51

The cash burn is still going to be 2/3 million per quarter. Staff costs are huge. The touted massive clinical trials revenue was from a cancelled contract. So they've got to get the pulse product launched and orders coming in, end of story. Band will cost more money and feels so far away its not going to make any difference short/medium term. I also added 100k shares to lower my average because at 20m MC and 14m cash its a good bet ( in my opinion ) but they seriously need to start delivering,

Hopeful and can see the potential but also prepared to cut and run.